Frequently Asked Questions
The global oncology small molecule drug market was valued at USD 76.5 Billion in 2022.
The oncology small molecule drug market is expected to grow at a CAGR of 5.80% between 2023 and 2030, reaching USD 113.51 Billion in 2030.
Targeted therapy drug is the leading segment by drug class, holding around half the share in value in 2022.
The hospital pharmacies segment governs the demand for oncology small molecule drugs worldwide, holding a massive share of nearly 55% in 2022.
The retail pharmacies segment is expected to post the highest CAGR during the forecast period.
North America is fueling the growth of the oncology small molecule drug industry, with a nearly two-fifth share in 2022.
The top players include Otsuka Pharmaceutical Co. Ltd, Eli Lilly and Co, Janssen Research and Development LLC, Novartis AG, Pfizer Inc., SANOFI AVENTIS US LLC, Baxter Healthcare Corp., Emcure Pharmaceuticals Ltd., AstraZeneca, Kyowa Kirin Inc., and HQ Specialty Pharma Corp and others
The Increasing prevalence of cancer worldwide is the major market driver.
High cost of oncology small molecule drug development restraints of oncology small molecule drug industry.
Advances in molecular biology, genomics, and drug discovery techniques are opportunities for the oncology small molecule drug industry.